✓ Translated by DotMD AI Clinical Council Source: Ophthalmology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42379522 ↗

Phase III Randomized Trial: Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy

Original Paper Title: “Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Greater baseline total and partial EZ attenuation were associated with higher rates of GA growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. ACP reduced EZ loss and degradation over 12 months versus sham.
  • Study Design & Sample: Phase III Randomized Trial published in Ophthalmology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Ophthalmology (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Ellipsoid zone (EZ) integrity is a key biomarker and surrogate for photoreceptor health, including in age-related macular degeneration. Key clinical takeaway: Greater baseline total and partial EZ attenuation were associated with higher rates of GA growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. ACP reduced EZ loss and degradation over 12 months versus sham.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Ophthalmology, 2026-11-15; Phase III Randomized Trial; Rigor 82/100): Greater baseline total and partial EZ attenuation were associated with higher rates of GA growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. ACP reduced EZ loss and degradation over 12 months versus sham.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: avacincaptad-pegol → Rx: fluorescein-sodium-and-benoxinate-hydrochloride → Rx: fluorescein-sodium → Condition: vision-blurred → Condition: eustachian-tube-dysfunction →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42379522: Phase III Randomized Trial: Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy

3 of 3 Free Questions Remaining